Emma Andrus, Editor

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

The phase 2 trial of bimiralisib gel shows promising efficacy and safety for actinic keratosis, with up to 70% lesion clearance.

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Among the many sessions to be held at the American Academy of Dermatology Annual Meeting in Orlando, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

Experts discussed laser and light-based therapies for acne, rosacea, hyperpigmentation, and inflammatory skin diseases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At AAAAI/WAO 2025, Bernstein explored new findings on rilzabrutinib and dupilumab in CSU, highlighting treatment gaps and future therapies.

A new survey reveals widespread misunderstanding and lack of effective treatments in chronic hand eczema.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Phase 3 trial results presented at AAAAI/WAO 2025 highlight dupilumab's efficacy in reducing itch severity and urticaria activity in CSU patients.

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of March.

Dermatology Times is recapping our top expert interviews from the month of February.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.